Sarcopenia and frailty in older patients with diabetes mellitus.

Sarcopenia is defined as age-associated loss of muscle mass and function, and is frequently accompanied by diabetes mellitus (DM) in older adults. Som...
564B Sizes 1 Downloads 14 Views

Recommend Documents


Sarcopenia, Frailty, and Diabetes in Older Adults.
Populations are aging and the prevalence of diabetes mellitus is increasing tremendously. The number of older people with diabetes is increasing unexpectedly. Aging and diabetes are both risk factors for functional disability. Thus, increasing number

Counteracting the Trajectory of Frailty and Sarcopenia in Older Adults.
Food preservation technologies and medical advances in the past 50 years have contributed to safeguarding the health and prolonging the lives of individuals worldwide. However, living longer does not automatically equate with being healthy, living in

Sarcopenia and frailty in elderly trauma patients.
Sarcopenia describes a loss of muscle mass and resultant decrease in strength, mobility, and function that can be quantified by CT. We hypothesized that sarcopenia and related frailty characteristics are related to discharge disposition after blunt t

[Sarcopenia and frailty in neurology].
Sarcopenia and frailty are common geriatric syndromes and are associated with adverse health outcome and impaired health-related quality of life. Co-occurrences of these two syndromes with age-related neurological diseases are potentially high but no

Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.
Population aging is rapidly accelerating worldwide; however, longer life expectancy is not the only public health goal. Indeed, extended lifetime involves maintaining function and the capacity of living independently. Sarcopenia and physical frailty

Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study.
In the coming decades, the population of older adults with type 2 diabetes mellitus is expected to grow substantially. Understanding the clinical course of diabetes in this population is critical for establishing evidence-based clinical practice reco

PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.
Sarcopenia and frailty often co-exist and both have physical function impairment as a core component. Yet despite the urgency of the problem, the development of pharmaceutical therapies for sarcopenia and frailty has lagged, in part because of the la